Joint Formulary & PAD

Tocilizumab - Rheumatoid arthritis

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red
Formulations :
  • Intravenous infusion
Associated Icons :
Restrictions / Comments :

PAD Profile

ChemicalSubstance :
Tocilizumab
Indication :
Rheumatoid arthritis
Group Name :
Keywords :
RA, Biologic, NICE, immunosuppressant, Interleukin-6 inhibitor, DMARD, bDmard, Disease modulating, Rheumatology, cytokine modulator
Brand Names Include :
RoActemra, Tyenne
Important Information :
Severe disease only
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
3

Other Indications

Below are listed other indications that Tocilizumab is used to treat.

Committee Recommendations (2)

The Surrey Heartlands Integrated Care System Area Prescribing Committee agreed the reviewed and updated rheumatoid arthritis pathway.

The Surrey Heartlands ICS Area Prescribing Committee have agreed an update of the Rheumatoid Arthritis High Cost DMARDs Drug Treatment Pathway. 

The pathway has been updated following guidance from the Regional Medicines Optimisation Committee in May 2020, in relation to the sequential use of biologic medicines.